SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): September 9, 2003

OraSure Technologies, Inc.

(Exact name of issuer as specified in charter)

DELAWARE (State or Other Jurisdiction

001-16537 (Commission file number) 36-4370966 (I.R.S. Employer

of Incorporation or Organization)

Identification Number)

220 East First Street

Bethlehem, Pennsylvania 18015-1360

(Address of principal executive offices)

(610) 882-1820

Edgar Filing: ORASURE TECHNOLOGIES INC - Form 8-K

 $(Registrant \ \ s \ telephone \ number, including \ area \ code)$

Edgar Filing: ORASURE TECHNOLOGIES INC - Form 8-K

Item 5 Other Events and Regulation FD Disclosure.

OraSure Technologies, Inc. (the Company) issued a press release announcing the receipt of U.S. Food and Drug Administration approval of the Company s OraQuic® Rapid HIV-1 Antibody Test for use with venipuncture whole blood samples. The information contained in the press release dated September 9, 2003 is incorporated herein by reference and attached to this Current Report on Form 8-K as Exhibit 99.

Item 7. Financial Statements and Exhibits

(c) Exhibits

Exhibit Number	Description
99	Press Release dated September 9, 2003, announcing receipt by OraSure Technologies, Inc. of U.S. Food and Drug Administration approval of its OraQuick® Rapid HIV-1 Antibody Test for use with venipuncture whole blood samples.

Edgar Filing: ORASURE TECHNOLOGIES INC - Form 8-K

Signatures		
Pursuant to the requirements of the Secu the undersigned, hereunto duly authorize		rant has duly caused this report to be signed on its behalf by
	OraSure Technologies, Inc	c.
Date: September 9, 2003	By:	/s/ Jack E. Jerrett
		Jack E. Jerrett
		Senior Vice President General Counsel and Secretary

Index to Exhibits

Exhibit Number	Description
99	Press Release dated September 9, 2003, announcing receipt by OraSure Technologies, Inc. of receipt of U.S. Food and Drug Administration approval of its OraQuick® Rapid HIV-1 Antibody Test for use with venipuncture whole blood samples.